not trying to be a ****,, but could you get me a link to those studys please, it sounds interesting..!
Here's one a of around a dozen. I'm too lazy to mull through documents to find them all but this one should suffice. The abstract mentions the exact AI used, the duration and even the daily dose. I have enough anecdotal evidence to be convinced this will work and enough confidence to try it on my own kids should they be willing.
1: J Clin Endocrinol Metab. 2005 Dec;90(12):6396-402. Epub 2005 Sep 27.
Inhibition of estrogen biosynthesis with a potent aromatase inhibitor increases
predicted adult height in boys with idiopathic short stature: a randomized
controlled trial.
Hero M, Norjavaara E, Dunkel L.
Hospital for Children and Adolescents, University of Helsinki, Finland.
CONTEXT: In males as well as in females, estrogen is an essential regulator of
bone maturation, growth plate fusion, and cessation of longitudinal growth.
Therefore, an increase in predicted adult height (PAH) may be achieved in short
boys by blocking estrogen biosynthesis. OBJECTIVE: We tested the hypothesis that
a decrease in the rate of bone maturation and an increase in PAH can be achieved
in boys with idiopathic short stature (ISS) by the method of blocking estrogen
biosynthesis with an aromatase inhibitor. Secondarily, we investigated the
effects of aromatase inhibition on bone mineralization. DESIGN: This was a
prospective, double-blind, randomized, placebo (Pl)-controlled clinical study.
SETTING: The study was performed at a university hospital out-patient clinic.
PATIENTS: Thirty-one boys, aged 9.0-14.5 yr, with ISS were studied. INTERVENTION:
The boys were treated with the aromatase inhibitor letrozole (Lz; 2.5 mg/d) or Pl
for 2 yr. MAIN OUTCOME MEASURE: The main outcome measure was the change in PAH
after 24 months of treatment. RESULTS: PAH increased by 5.9 cm (P < 0.0001), and
height SD score for bone age increased by 0.7 SD score (P < 0.0001) in the
Lz-treated boys, whereas no changes occurred in the respective measures in
Pl-treated boys. Areal bone mineral density of the lumbar spine and femoral neck,
assessed by dual-energy x-ray absorptiometry, increased in a similar fashion in
both groups during the treatment, whereas bone mineral apparent density increased
only in those taking Lz (median increase, 4.3%; P = 0.009). CONCLUSIONS:
Treatment with the aromatase inhibitor Lz delays bone maturation and improves PAH
in boys with ISS. No adverse effects on bone mineralization were evident after 2
yr of treatment.